Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2a - Amarillo/Hayashibara

Drug Profile

Interferon alpha-2a - Amarillo/Hayashibara

Alternative Names: IFN-alpha lozenges; MOR 22; Natural human lymphoblastoid interferon-alpha; Veldona

Latest Information Update: 28 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hayashibara
  • Developer Amarillo Biosciences; CytoPharm; Hayashibara; Mochida Pharmaceutical; NOBEL ILAC; Otsuka Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Human papillomavirus infections; Polycythaemia vera; Behcet's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Myeloid leukaemia; Renal cell carcinoma
  • Phase II Influenza virus infections
  • No development reported Behcet's syndrome; Solid tumours; Thrombocytopenia
  • Discontinued Chronic obstructive pulmonary disease; Fibromyalgia; HIV infections; Human papillomavirus infections; Liver cancer; Polycythaemia vera; Pulmonary fibrosis; Sjogren's syndrome; Skin disorders; Thrombocytosis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in Thrombocytopenia in USA (PO, Lozenge)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (PO, Lozenge)
  • 03 Aug 2017 Amarillo Biosciences files for second Continuation Application with the USPTO for low-dose oral interferon alpha in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top